The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

Abstract Recently, we reported the phase II portion of the adaptive phase II/III PANAMO trial exploring potential benefit and safety of selectively blocking C5a with the monoclonal antibody vilobelimab (IFX‐1) in patients with severe coronavirus disease 2019 (COVID‐19). The potent anaphylatoxin C5a...

Full description

Bibliographic Details
Main Authors: Alexander P. J. Vlaar, Endry H. T. Lim, Sanne deBruin, Simon Rückinger, Korinna Pilz, Matthijs C. Brouwer, Ren‐Feng Guo, Leo M. A. Heunks, Matthias H. Busch, Pieter vanPaassen, Niels C. Riedemann, Diederik van deBeek
Format: Article
Language:English
Published: Wiley 2022-04-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13213

Internet

https://doi.org/10.1111/cts.13213

Similar Items